PubMed Health⌕ Search

Biomedical subjects

N Scott

Publications and source records attributed to N Scott.

74 records · Page 5Linked to original sources

Increased activity of oxygen free radicals during reperfusion in patients with peripheral arterial disease undergoing percutaneous peripheral artery balloon angioplasty.

Modern balloon angioplasty plays an important role in the treatment of localized arterial lesions in patients with peripheral vascular disease (PVD). However, the process of angioplasty produces a situation of acute ischaemia followed by reperfusion and animal studies have shown such situation to be associated with an increase in free radical (FR) generation. FRs cause tissue damage and may be prothrombotic and may therefore contribute to the occurrence of restenosis. Release of FRs during reperfusion has not been fully investigated in humans. We studied the FR activity in 44 patients with PVD in the superficial or popliteal arteries receiving angioplasty treatment. Thirty patients had stenotic lesions and 14 had totally occlusive disease. Baseline blood samples were taken from the arterial catheter for the assay of malondialdehyde (MDA) (spectrophotometric thiobarbituric acid assay) immediately before and after balloon inflation. MDA is a measure of lipid peroxidation which is an indicator of FR activity. MDA levels during reperfusion were significantly higher than those immediately prior to balloon inflation [8.4 (0.29) vs 8.1 (0.24) mumol/l, respectively; mean increase--0.34 (0.13) mumol/l; [mean (sem)] p less than 0.01 (paired Wilcoxon rank test)] in the stenotic lesions. Such changes were not observed in the totally occlusive lesions [7.26 (0.39) vs 7.26 (0.48) mumol/l, respectively; p = 0.75]. Our study has shown increased FR release following angioplasty in patients with stenotic, but not occlusive, peripheral vascular lesions. Angioplasty of the stenotic lesions creates++ a situation of acute ischaemia and reperfusion whereas that of the occlusive lesions leads to the reperfusion of a chronically ischaemic area.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis--a preliminary study.

Prostacyclin (PGI2) and its analogues are useful treatments for patients with secondary Raynaud's syndrome (RS). However, they have to be given intravenously, causing inconvenience to patients. Cicaprost is an orally available analogue of PGI2 and has been shown to inhibit platelet aggregation in both in vitro and animal studies. We recently investigated the effects of cicaprost on whole blood platelet aggregation, red cell deformability, white cell function (polymorphonuclear cell aggregation, elastase release and free radical activity) and plasma fibrinolysis in 14 patients with systemic sclerosis (SSc) and secondary RS. Patients received cicaprost (2.5 micrograms or 5 micrograms t.i.d.) or matching placebo tablets orally for 10 days. Blood samples were taken at baseline and 2 hours after administration of the last treatment for the above mentioned assays. No changes were observed in any of the cellular elements and parameters measured in the 3 groups of patients studied. Our study suggests that cicaprost, at doses up to 5 micrograms t.i.d., fails to modify the blood coagulation elements and factors in patients with RS secondary to SSc. Further studies using higher doses and longer study periods are planned.

Administration, Oral↗